### **Q1 Conference Call** Probi continues on its successful growth path

Peter Nählstedt, CEO Dr. Jörn Andreas, CFO

Lund, 4 May, 2017



### Safe Harbor Statement

This presentation contains certain forward-looking information that reflects Probi's present view of future events, as well as financial and operational development. Words such as "intend", "assess", "expect", "may", "plan", "believe", "estimate" and other expressions entailing indications or predictions of future development or trends, not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information is not a guarantee of future results or development and actual outcomes may differ materially from the statements set forth in the forward-looking information. Given the risks associated with forward-looking statements, recipients of this presentation are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements referred to above speak only as at the date of the presentation. Probi will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect future events, circumstances, anticipated events, new information or otherwise except as required by law or by any appropriate regulatory authority.

Probi does not make any guarantee, representation or warranty, express or implied, as to the accuracy, completeness or fairness of the information and opinions contained in this presentation, and no reliance should be placed on such information. Probi does not accept any responsibility or liability whatsoever for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection therewith.



### Introduction – Conference call participants



Peter Nählstedt CEO



Dr. Jörn Andreas CFO



3

1	Executive overview
2	Financial review
3	Outlook
4	Q&A



### Probi – First in Probiotics



- The only top fully integrated probiotics player solely focused on probiotics in one of the most interesting sectors of health
- Agility of a small company with an ownership structure allowing the strengths of a major international group
- Strong, forward looking culture living our corporate values





**130 MSEK** EBIT 2016





**34%** EBITDA margin 2016

200 Employees 2016






4 global Centers of Excellence




## Highlights of Q1 2017 - successful start to 2017

#### **Net sales**

MSEK, sales growth in % (local currency growth in %)



#### **EBITDA**



MSEK, EBITDA margin as % of Group net sales

#### Key developments during the quarter


- Significant increase in sales and earnings driven by Nutraceutix acquisition and organic growth
- Market launch of patented and clinically documented Probi Select<sup>™</sup> product range in North America
- Start of strategic initiatives to continue delivering long-term growth:
  - Increase of manufacturing capacity in the USA
  - Design and implementation of new Group enterprise system (ERP)



## Continued strong performance of Consumer Healthcare

#### Net sales by segments

MSEK, sales growth in %



#### Key aspects

- Acquired operations contributed MSEK 72 to CHC segment sales
- Strong organic growth in CHC exceeding 38% driven by promotional activities and favorable underlying volume growth
- FF impacted by lower royalty rate which offset favorable volume growth across all regions



## Regional results – strongest growth in Europe

Net sales by segments MSEK, sales growth in % **Rest of Europe** North America Sweden RoW +162% 154.1 58.8 -16% +5% +179% 14.8 12.4 10.9 10.0 9.5 3.9 Q1 2016 Q1 2017 Q1 2016 Q1 2017 Q1 2016 Q1 2017 Q1 2016 Q1 2017 % of Group 68% 82% 17% 7% 5% 6% 11% 5% net sales



### Launch of Probi Select<sup>™</sup> in North America



- Three of Probi's existing and not commercialized probiotic platforms supporting immune and digestive health
- Patent-protected and supported by clinical documentation
- Designed to bring competitive health benefits to a broad target group
- Well-positioned in the USA after acquisition to make use of market opportunities



## Start of strategic initiatives to continue long term growth

#### Capacity expansion in the US



- Serve volume and quality requirements of our customers in the long-term
- Complements ongoing process and yield requirements

Implementation of Group enterprise system

### **ONE** Probi

- Create more agile business processes
- Take full advantage of the integrated supply chain and manufacturing excellence post-acquisition




1	Executive overview
2	Financial review
3	Outlook
4	Q&A



## Favorable start to the new fiscal year 2017

#### Probi sales bridge

MSEK, change in %



#### Condensed P&L


MSEK, change in %

	Q1 2017	Q1 2016	Change
Net sales	187.4	87.0	115%
EBITDA	62.4	36.9	<b>6</b> 9%
EBITDA margin	33.3%	42.5%	<b>920bps</b>
EBIT	56.0	35.3	<b>5</b> 9%
Net income	47.8	26.9	<b>1</b> 78%
EPS	4.20	2.95	42%



## Significant increase in net income driven by acquisition

### Reconciliation of net income




#### Key aspects

- EBIT increase due to organic growth and acquisition
- PPA results expected to be provided in Q2 2017 and will impact EBIT going forward
- Positive financial result due to by favorable realization of forward contract (hedging of financial receivable)



## Strong operating cash flow generation in Q1 2017

#### **Reconciliation of group liquidity Q1 2017** MSEK



#### **Key aspects**

- Increase of CCE driven by increased sales but adversely affected by increased taxes paid
- Gross operating cash flow includes MSEK 14 cash gain resulting from favorable realization of forward contract (hedging of financial receivable)



### Balance sheet: PPA expected to be recognized in Q2 2017

#### **Balance sheet Probi Group**

MSEK, in % of total assets

Assets	31 March 2017	31 March 2016	Liabilities and equity	31 March 2017	31 March 2016
Intangibles (excl. GW)	75	46	Total equity	938	214
Goodwill	786	3	Other non-current liabil.	1	—
PPE	41	4	Deferred tax liabilities		0
Deferred tax assets	5	_	Non-current liabilities	1	0
Non-current assets	906	53	Borrowings	222	_
Inventories	75	5	Trade payables	42	17
Trade receivables	99	39	Other current liabilities	36	24
Other current assets	10	5	Current liabilities	300	41
Cash and cash equiv.	149	153	Total liabilities	301	41
Current assets	334	202			
Total assets	1,239	255	Liabilities and equity	1,239	255

#### **Key aspects**

- Net financial debt MSEK 74
- Leverage ratio<sup>1</sup> of 0.3x LTM EBITDA
- Total equity of MSEK 938
- Equity ratio 76%

1. Leverage ratio = Net financial debt div

15




1	Executive overview
2	Financial review
3	Outlook



## Continue with strong 2017 goals


#### **Probi Growth Strategy**




#### **2017 Priorities**



Continue the Probi growth story with focus on Asia



Fully realize the existing synergies between Probi USA and Probi Sweden





1	Executive overview
2	Financial review
3	Outlook
4	Q&A



